Bai-jun Fang

Department Of Head Neck And Thyroid
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.

Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.

Journal: World journal of surgical oncology

Published: May 19, 2025

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.

Journal: Cancer medicine

Published: February 01, 2025

Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.

Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.

Journal: Asian journal of surgery

Published: June 15, 2023

Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma.

Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma.

Journal: Journal of inflammation research

Published: March 31, 2023

Research Progress of Clonal Hematopoiesis of Indeterminate Potential in Multiple Myeloma --Review

Research Progress of Clonal Hematopoiesis of Indeterminate Potential in Multiple Myeloma --Review

Journal: Zhongguo shi yan xue ye xue za zhi

Published: April 09, 2022

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.

Journal: BMC cancer

Published: December 16, 2021

PX-12 Promoting Apoptosis of Multiple Myeloma Cell Line H929 Induced by Bortezomib

PX-12 Promoting Apoptosis of Multiple Myeloma Cell Line H929 Induced by Bortezomib

Journal: Zhongguo shi yan xue ye xue za zhi

Published: April 04, 2021

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.

Journal: Leukemia

Published: September 29, 2020

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.

Journal: European journal of haematology

Published: March 18, 2020

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods.

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods.

Journal: Cancer management and research

Published: June 11, 2019

Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.

Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.

Journal: Chinese medical journal

Published: March 22, 2019

The role of long non-coding RNAs in multiple myeloma.

The role of long non-coding RNAs in multiple myeloma.

Journal: European journal of haematology

Published: February 27, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026